The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Macrophage to feces Reverse Cholesterol Transport

Macrophage-to-feces Reverse cholesterol transport

State-of-the-art technique to directly demonstrate that your compound promotes reverse cholesterol transport and has therefore the potential to prevent cardiovascular diseases.

key benefits

  • In vivo reverse cholesterol transport using 3H-labeled cholesterol is the best approach to evaluate compounds affecting HDL metabolism and reverse cholesterol transport.
  • Demonstrate beneficial effects of your compound on macrophage-to-feces reverse cholesterol transport.
  • Essential and robust data to demonstrate that your compound promotes the transport of cholesterol from peripheral tissues to the feces and has therefore the potential to prevent atherosclerosis.

Description and parameters

In vivo reverse cholesterol transport using radiolabeled cholesterol is the best approach to evaluate compounds affecting HDL metabolism and reverse cholesterol transport.

Species

  • Hamster
  • Mouse
  • Rat

Macrophage to feces Reverse Cholesterol Transport method

Macrophage to feces Reverse Cholesterol Transport
Macrophage to feces Reverse Cholesterol Transport

Parameters evaluated

  • Plasma total cholesterol, HDL-c and HDL-c/TC ratio
  • ³H-cholesterol appearance from macrophage to plasma and liver
  • Macrophage-derived cholesterol fecal excretion: ³H-tracer recovered in fecal free sterols and bile acids

Add-on studies

Fact sheet

Macrophage to feces reverse Cholesterol Transport Physiogenex

REFERENCES

Briand F. et al. Eur J Pharmacol. 2014, 740: 135–143.
ico-link
Briand F. et al, J Nutr. 2012 Apr;142(4): 704-709.
Briand F. et al, Diabetes Obes Metab, 2012, 14(7):662-5.
Briand F. et al, Clin Transl Sci. 2011 Dec;4(6): 414-420.
Briand F. et al, J Lipid Res. 2011 Nov;52(11):1965-73.
Nijstad N. et al, Gastroenterology. 2011 Mar;140(3):1043-51.
Tréguier M. et al, Eur J Clin Invest. 2011 Sep;41(9):921-8.
Briand F. et al, J Lipid Res. 2010 Apr;51(4):763-70.